Evidence map›Paper›PMID 41888525›Full record

ArticleBlood cancer journal2026

Low-dose CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: a single-arm, open-label, phase Ia/Ib study.

Fan Yang, Rui Liu, Zhonghua Fu, Yuelu Guo, Lixia Ma, Miaomiao Cao, Biping Deng, Alex H Chang, Haifeng Wu, Shilin Gan and 3 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Fan YangDepartment of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, China.
Rui LiuDepartment of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, China.
Zhonghua FuDepartment of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, China.
Yuelu GuoDepartment of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, China.
Lixia MaDepartment of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, China.
Miaomiao CaoDepartment of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, China.
Biping DengCytology Laboratory, Beijing GoBroad Boren Hospital, Beijing, China.
Alex H ChangShanghai YaKe Biotechnology Ltd, Shanghai, China.ORCID http://orcid.org/0000-0002-7572-309X
Haifeng WuDepartment of Biostatistics, GoBroad Research Center, Beijing, China.
Shilin GanDepartment of Biostatistics, GoBroad Research Center, Beijing, China.
Chen ChenDepartment of Biostatistics, GoBroad Research Center, Beijing, China.
Xiaoyan KeDepartment of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, China.
Kai HuDepartment of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, China. huk@gobroadhealthcare.com.ORCID http://orcid.org/0000-0002-2777-9080

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41888525
PMCPMC13021992

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.